- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04664543
Efficacy of Free Versus Low Residue Diet as Preparation for Screening Colonoscopy (CriLi)
Efficacy of Free Versus Low Residue Diet as Preparation for Screening Colonoscopy: CriLi Study, a Pilot Trial
One tricky aspect of the recommendations for colonoscopy prep is diet. This has a significant impact on the experience of the patient or participant in the screening program and, on the other hand, low adherence has been found in some studies despite a potential Hawthorne effect . It is noteworthy that despite its impact on patient experience, it is an area for which little evidence is available, which is why the guidelines give low-quality recommendations and there is probably considerable variability in clinical practice .
In the early days of colonoscopy, a liquid diet for 48 hours was mainly recommended, although some centers indicated a low-residue diet or even the commercially available NASA astronaut diet. Later, the indication for a liquid diet was consolidated until finally numerous studies were published in favor of a low-residue diet, managing to increase tolerance and the quality of the preparation . A limitation of the preparation studies must be borne in mind that the colon cleansing rating scales were not introduced until 1999 when the Aronchick scale was published.
Although there is solid evidence in favor of a low-residue diet versus a liquid diet, the investigators do not have evidence on how many days of a low-residue diet should be recommended, and this is reflected in the ESGE (European Society of Gastrointestinal Endoscopy) and ASGE (American Society of Gastrointestinal Endoscopy) guidelines . A randomized clinical trial comparing 3 days versus 1 day of a low residue diet has recently been published . There were no statistically significant differences in the rate of adequate preparations (82.7% vs. 85.6% OR 1.2 95% IC 0.72 to 2.15). However, this study has limited statistical power and a design that allows a non-inferiority analysis has not been followed. In relation to this, our research group is finalizing a non-inferiority clinical trial in whose intermediate analysis, with 421 participants, the non-inferiority of 1 day of diet is fulfilled (rate of poor preparation in 1 day 0.95% vs. 4.74% in 3 days; d + 5%, difference -3.78% IC -6.88% to -1.12%) (38).
It is likely, taking into account the available evidence and its evolution, that diet plays a secondary role in preparation. Although no studies designed to directly assess this have been conducted, the research group has indirect data.
Walter et al, under the hypothesis that the impact of the fractional preparation and the new preparations on the preparation diminished the importance of the diet, conducted a non-inferiority clinical trial between 2012 and 2013 in which they randomized the patients to follow a diet liquid versus low residue for one day and fractional preparation with Moviprep (39). They established a non-inferiority margin of -13.5%. Their results show a rate of good preparation (Boston> 5) in 68/72 (94.4%) in a liquid diet compared to 60/68 (88.2%) in a low-residue diet (p = 0.04) with a difference of -5.08% demonstrating non-inferiority of the low residue diet.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Barcelona
-
Sabadell, Barcelona, Spain, 08208
- Hospital Universitari Parc Taulí
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women between 50 and 69 years old.
- Participants in the Program for the Early Detection of Colorectal Cancer with a positive result in the test for detecting occult blood in feces
- That they accept a colonoscopy and that they agree to participate in the study.
Exclusion Criteria:
- Contraindication to performing a colonoscopy.
- Severe renal insufficiency (<30 ml / min).
- Known hypersensitivity or allergy to polyethylene glycol, ascorbic acid or sulfate.
- Known glucose-6-phosphate dehydrogenase deficiency.
- Known phenylketonuria.
- Known dyselectrolytemia: hyper / hyponatremia, hyperphosphatemia, hypermagnesemia, hyper / hypokalemia, hypocalcemia.
- Gastric emptying disorders: Known gastroparesis.
- Known hypoalbuminemia less than 3.4 g / dl.
- Crohn's disease or known ulcerative colitis.
- Participants with difficult-to-control hypertension (SBP> 170mmHg or TAD> 100mmHg) or NYHA grade III or IV heart failure.
- Ascites of any etiology
- People with cognitive impairment or mental illness that makes it difficult to adhere to instructions.
- People who do not understand Catalan or Spanish.
- Factors of poor preparation: liver cirrhosis, diabetes mellitus, treatment with tricyclic antidepressants, opioids or neuroleptics, limited mobility, chronic constipation, history of colon or intestinal resection (appendectomy is not an exclusion criterion), poor preparation in previous colonoscopy Parkinson's disease, multiple sclerosis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: 3 days of low residue diet
Currently participants in the colorectal cancer screening program follow a 3 days low residue diet before colonoscopy.
This is the active comparator arm of this study.
|
To follow the three days before colonoscopy a diet with low content in fiber or residues.
Other Names:
|
EXPERIMENTAL: Free diet
Participants assigned to this arm are NOT instructed to follow any kind of restriction in the diet before colonoscopy.
|
To follow the regular dietary habits with no restriction nor modification.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adequate bowel cleansing
Time Frame: During colonoscopy (At the withdrawal phase)
|
Bowel cleansing has a rating using the Boston Bowel Preparation Scale above 1 in each segment .
This score ranges fron 0 to 3 in each one of the three segments.
Zero is the worst outcome and 3 is the best cleansing
|
During colonoscopy (At the withdrawal phase)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Withdrawal time
Time Frame: During colonoscopy
|
Time expended in the withdrawal from cecum till the anus.
|
During colonoscopy
|
Diet tolerability
Time Frame: The day of the colonoscopy just before beginning
|
Tolerance to the diet assigned to the participant measured with a likert scale from 0 to 5, 0 the worst ad 5 the best.
|
The day of the colonoscopy just before beginning
|
Preparation tolerability
Time Frame: The day of the colonoscopy just before beginning
|
Tolerance to the cleansing solution used for bowel cleansing measured with a likert scale from 0 to 5, 0 the worst ad 5 the best.
|
The day of the colonoscopy just before beginning
|
Adenoma detection
Time Frame: adenoma detection is done during the colonoscopy but assesment will be done at the end of the study with the histology reports
|
An adenoma was detected, resected and confirmed by the histology report in the colonoscopy.
|
adenoma detection is done during the colonoscopy but assesment will be done at the end of the study with the histology reports
|
Polyp detection
Time Frame: During colonoscopy
|
Polyp detection in the colonoscopy as reported by the endoscopist.
|
During colonoscopy
|
Ceacal intubation time
Time Frame: During colonoscopy
|
Time expended in reaching the cecum
|
During colonoscopy
|
Excellent cleansing
Time Frame: During colonoscopy
|
Colonoscopy achieving a Boston Bowel Preparation Scale (BBPS) of at least 8 points or above.
BBPS global score ranges from 0 to 9, being 9 the best cleansing outcome.
|
During colonoscopy
|
Information perceived quality
Time Frame: The day of the colonoscopy just before beginning
|
Perceived quality of the instructions and education received for the colonoscopy.
preparation by the participant.
Assessed using a likert scale from 0 to 5. Five is the best outcome and 0 the worst.
|
The day of the colonoscopy just before beginning
|
Preparation quality in each segment
Time Frame: During colonoopy
|
Boston Bowel Preparation Score in each segment, it ranges from 0 to 3 being 3 the best cleansing outcome and 0 the worst.
|
During colonoopy
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Eva Martínez, PhD, Hospital Universitari Parc Taulí
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019307
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Cancer
-
University of California, San FranciscoCompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRectal Cancer | Colon Cancer | Cancer Survivor | Colorectal Adenocarcinoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedCancer Survivor | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal Cancer AJCC v8 | Stage IIB Colorectal... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingColorectal Adenocarcinoma | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Neoplasms Malignant | Colorectal Cancer Stage IUnited States, Japan, Italy, Spain
-
University of Roma La SapienzaCompletedColorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Cancer Stage 0 | Colorectal Cancer Stage IItaly
-
Sidney Kimmel Cancer Center at Thomas Jefferson...United States Department of DefenseActive, not recruitingColorectal Adenoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage 0 Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); AmgenTerminatedStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer...United States
Clinical Trials on Three days low residue diet
-
Changhai HospitalThe First Affiliated Hospital with Nanjing Medical University; First Affiliated... and other collaboratorsCompleted
-
Cedars-Sinai Medical CenterRecruitingImplementing a Low Fiber Diet vs. Regular Diet in Postoperative Colorectal Patients With IleostomiesIleostomy; Complications | Bowel Obstruction | Postoperative IleusUnited States
-
University of Roma La SapienzaCompletedCesarean Section ComplicationsItaly
-
michal rollUnknown
-
Hospital Parc Taulí, SabadellCompletedColorectal Neoplasms | Inflammatory Bowel Diseases | Colonoscopy | Colon Adenoma | Colon DiseaseSpain
-
Newcastle UniversityNewcastle-upon-Tyne Hospitals NHS TrustCompleted
-
Cedars-Sinai Medical CenterCompleted
-
National Taiwan University HospitalCompletedDietary ModificationTaiwan
-
Portuguese Oncology Institute, CoimbraCompletedColonic Neoplasms | Colon DiseasePortugal
-
Hamilton Health Sciences CorporationMcMaster UniversityUnknownAnastomotic Leak | Surgical Site InfectionCanada